The impact of Brexit on the supply chain

Synopsis

Brexit has had significant impact on the pharmaceutical industry, with particular impact on the supply chain covering both import and export.
The UK is now considered a third country and the impact of this includes increased inspection for competent health authorities, changes to supply routes, changes to medicines offered in specific markets and changes to process (for example, EU QP release and testing, and RPi).
The Windsor Framework focuses specifically on the continued supply into Northern Ireland and Republic of Ireland, and there has been significant impact to the supply chain including longer lead times, reduced range and increased process (to increase even further from January 2025).
A requirement for the greater focus on supply chain mapping.